Procaterol and terbutaline in bronchial asthma. A double-blind, placebo-controlled, cross-over study.
Procaterol, a new beta-2 adrenoceptor stimulant, was studied in a double-blind, placebo-controlled, cross-over trial in patients with bronchial asthma. Oral procaterol 50 micrograms b.d., procaterol 100 micrograms b.d., and terbutaline 5 mg t.i.d., were compared when given randomly in 1-week treatment periods. The best clinical effect was found with terbutaline. Both anti-asthmatic and tremorgenic effects of procaterol were dose-related. Procaterol appeared effective in the doses tested, and a twice daily regimen would appear to be suitable with this drug.
Dahl
R
R
Harving
H
H
Henriksen
J
J
Rønne
K
K
Schøler
P
P
D000293:Adolescent; D000328:Adult; D000368:Aged; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004983:Ethanolamines / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010366:Peak Expiratory Flow Rate; D017265:Procaterol; D013726:Terbutaline / Q000009:adverse effects / Q000627:therapeutic use*; D014202:Tremor / Q000139:chemically induced
D004983:Ethanolamines; D013726:Terbutaline; D017265:Procaterol